Skip to main content
GutCited

Butyrate (Sodium/Calcium Butyrate) per Crohn's Disease

C

Oral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbutyrate\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

In sintesi

Oral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.

Key Study Findings

Randomized Controlled Trial n=140 Double-blind
Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study …
Dose: None vs: placebo plus conventional therapy Outcome: clinical disease activity and fecal calprotectin Effetto: None p=0.013

Popolazione: IBD patients (60 Crohn's disease, 80 ulcerative colitis)

In Vitro
Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting ferroptosis and modulating ERK/STAT3 signaling and …
Dose: Low-dose and high-dose NaB vs: DSS-induced IBD mice; 5-ASA control Outcome: IBD symptom alleviation and ferroptosis inhibition Effetto: None None

Popolazione: DSS-induced IBD murine model

In Vitro
Effects of Lactobacillus paracei JY062 Postbiotic on Intestinal Barrier, Immunity, and Gut Microbiota.
Dose: 5 mg/mL vs: LPS-treated cell models Outcome: Intestinal barrier function and gut microbiota Effetto: None None

Popolazione: Caco-2 cells, RAW264.7 macrophages, fecal fermentation

Other
Association of Inflammatory Factors and Calcium Metabolism With Arthritis in Patients With Inflammatory Bowel Disease: …
Dose: None vs: None Outcome: Causal associations IBD → arthritis subtypes (MR) Effetto: OR=1.21 (IBD→AS); OR=1.18 (IBD→PsA) <0.001 (AS); 0.007 (PsA)

Popolazione: Mendelian randomization study of IBD and arthritis

Observational Study n=212
Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology.
Dose: None vs: Healthy controls Outcome: CD-specific microbiome signatures (AUC 0.94) Effetto: AUC 0.94 in external validation None

Popolazione: Crohn's disease and ulcerative colitis patients

In Vitro
Effects of senotherapeutics on gut microbiome dysbiosis and intestinal inflammation in Crohn's disease: A pilot …
Dose: None vs: Untreated Crohn's disease microbiota Outcome: Gut microbiome modulation and inflammation Effetto: None None

Popolazione: Crohn's disease fecal microbiota in SHIME model

Key Statistics

2

Studi

200

Partecipanti

Positive

C

Grado

Referenced Papers

Langenbeck's archives of … 2025 3 citazioni
Current opinion in … 2019 5 citazioni
Current pharmaceutical design 2018 108 citazioni
Gastroenterology 2017 335 citazioni
Innate immunity 2017 13 citazioni
Alimentary pharmacology & … 2005 227 citazioni
Alimentary pharmacology & … 2003 179 citazioni
Current opinion in … 2001 45 citazioni
Current opinion in … 2000 21 citazioni
Diseases of the … 1998 26 citazioni
Digestive diseases (Basel, … 1993 29 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
150-600 mg/day sodium or calcium butyrate
ibdsupport:
300-600 mg three times daily (900-1,800 mg/day)
butyrateenema:
100 mM butyrate enema for distal UC (clinical setting only)

Limite massimo: No established upper limit for oral supplements; most studies use 600-4,000 mg/day

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None -- Positive 140
Low-dose and high-dose NaB -- Positive --
5 mg/mL -- Positive --
None -- Positive --
None -- Positive 212
None -- Positive --
None -- Negative --
None -- Mixed --

Momento migliore per l'assunzione: With meals; enteric-coated formulations recommended to reach the colon

Safety & Side Effects

Effetti collaterali segnalati

  • Unpleasant taste/odor (butyric acid has a strong rancid butter smell)
  • Mild GI discomfort (nausea, bloating)
  • Belching with butyric acid odor
  • Enteric-coated formulations reduce taste issues

Interazioni note

  • 5-ASA medications (mesalamine) — additive anti-inflammatory effect (potentially beneficial in IBD)
  • No significant adverse drug interactions known

Livello di assunzione massimo tollerabile: No established upper limit for oral supplements; most studies use 600-4,000 mg/day

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Butyrate (Sodium/Calcium Butyrate) help with Crohn's Disease?
Based on 2 studies with 200 participants, there is limited but promising evidence that Butyrate (Sodium/Calcium Butyrate) may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much Butyrate (Sodium/Calcium Butyrate) should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 150-600 mg/day sodium or calcium butyrate. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Butyrate (Sodium/Calcium Butyrate)?
Reported side effects may include Unpleasant taste/odor (butyric acid has a strong rancid butter smell), Mild GI discomfort (nausea, bloating), Belching with butyric acid odor, Enteric-coated formulations reduce taste issues. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Butyrate (Sodium/Calcium Butyrate) and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.

Related Evidence

Butyrate (Sodium/Calcium Butyrate) per altre condizioni

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.